While the world debates AI, Allozymes is quietly engineering biology itself—turning microfluidics into a high-throughput factory for evolving enzymes. They're not just writing code; they're rewriting proteins.

"They're solving the enzyme engineering bottleneck not with brute force, but with precision microfluidics."

The traffic data tells a revealing story. With only 2,921 monthly visits, Allozymes isn't chasing vanity metrics. Their 40% direct traffic suggests a concentrated, high-intent audience—likely biotech partners, pharma R&D teams, and academic collaborators. The 37% organic search comes from targeted queries like 'allozyme definition' (510 monthly volume), indicating they're educating the market while capturing demand.

• Microfluidics platform enables ultra-high-throughput enzyme screening
• Lean team structure (38 people) with strong revenue-per-employee metrics
• Strategic content marketing targeting technical decision-makers
• Backed by $23.3M from investors betting on biotech infrastructure plays